Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells

Murali Subramani, Murugeswari Ponnalagu, Lekshmi Krishna, Nallathambi Jeyabalan, Priyanka Chevour, Anupam Sharma, Chaitra Jayadev, Rohit Shetty, Nargis Begum, Govindaraju Archunan, Debashish Das*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number12242
Number of pages16
JournalScientific Reports
Volume7
DOIs
Publication statusPublished - 25 Sep 2017

Keywords

  • PIGMENT EPITHELIAL-CELLS
  • DIABETIC MACULAR EDEMA
  • TO-MESENCHYMAL TRANSITION
  • GROWTH-FACTOR PHARMACOTHERAPY
  • ACTIVATED POTASSIUM CHANNELS
  • DIFFERENT OCULAR CELLS
  • ANTI-VEGF THERAPY
  • CHOROIDAL NEOVASCULARIZATION
  • MEDIATED INHIBITION
  • OXIDATIVE STRESS

Cite this

Subramani, M., Ponnalagu, M., Krishna, L., Jeyabalan, N., Chevour, P., Sharma, A., Jayadev, C., Shetty, R., Begum, N., Archunan, G., & Das, D. (2017). Resveratrol reverses the adverse effects of bevacizumab on cultured ARPE-19 cells. Scientific Reports, 7, [12242]. https://doi.org/10.1038/s41598-017-12496-z